Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "Liver" returned 7 results:


A 36 month multi-center, open-label, randomized, comparator study to evaluate the efficacy and safety of everolimus immunosuppression treatment in liver transplantation for hepatocellular carcinoma exceeding Milan criteria
Principal Investigator(s): Dr. Sander Florman

Assessment of Response of Unresectable Hepatocellular Carcinoma Chemoembolization and Stereotactic Body Radiation Therapy
Principal Investigator(s): Dr. Michael H. Buckstein

A Multicenter, randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Levantinib (E7080) versus Sorafenib in First Line Treatment of Subjects with Unresectable Hepatocellular Carcinoma
Principal Investigator(s): Max W Sung

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma and Cholangiocarcinoma
Principal Investigator(s): Dr. Max Sung

Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib
Principal Investigator(s): Dr. Charissa Chang

Phase 3 Prospective, Randomized, Blinded And Controlled Investigation Of Hepasphere/Quadrasphere Microspheres For Delivery Of Doxorubicin For The Treatment Of Hepatocellular Cancer
Principal Investigator(s): Edward Kim

A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib
Principal Investigator(s): Myron Schwartz